

NEO-005 CON

BRACHYTHERAPY NEEDLE WITH IMPEDANCE MEASUREMENT
APPARATUS AND METHODS OF USE

Field Of The Invention

The present invention relates to apparatus
5 and methods for accurately depositing radioactive seeds
into a patient's prostate in the vicinity of the
patient's bladder.

Background Of The Invention

The American Cancer Society estimates that
10 over 198,000 new cases of prostate cancer will be
diagnosed in the United States in the year 2001 and
nearly 31,500 men will die. Excluding non-melanoma skin
cancers, prostate cancer is the most common cancer
afflicting men in the United States.

15 Prostate cancer is defined as malignant tumor
growth within the prostate gland. A staging system is a
standardized way in which the extent to which a cancer
is spread is described. The most commonly used system
in the United States is called the TNM System of the
20 American Joint Committee on Cancer. The TNM system
describes the extent of the primary tumor (T), the
absence or presence of metastasis to nearby lymph node
(N), and the absence or presence of distant metastasis.
(M).

There are four categories for describing the prostate cancer's T stage. In Stage T1, the tumor is not palpable but is detectable through prostate biopsy or prostatectomy specimen. In Stage T2, the cancer is palpable and is confined to the prostate. In Stage T3, the tumor extends locally beyond the prostate to the connective tissue next to the prostate and/or to the seminal vesicles, but does not involve any other organs. In Stage T4, the cancer has metastacized to the tissues next to the prostate such as the bladder's external sphincter, the rectum and/or the wall of the pelvis.

There are two N stages. Stage N0 indicates that the cancer has not spread to any lymph nodes. Stage N1 indicates the cancer has metastasized to one or more regional lymph nodes in the pelvis.

Finally, there are two M stages, M0 and M1. Stage M0 indicates that the cancer has not metastasized beyond the regional nodes. In comparison, Stage M1 means that metastases are present in distant (outside the pelvis) lymph nodes, in bones or other distant organs such as lungs, liver or brain.

In the early stages, prostate cancer is most commonly treated by either prostate removal or by brachytherapy. More advanced cases are treated by hormonal manipulation or orchiectomy to reduce testosterone levels and curb spreading of the disease, by chemotherapy, or by external beam radiation therapy.

With regard to treatment of early stage prostate cancer, the state of the art has several drawbacks. Radical prostatectomy is often recommended for treatment of localized stage A and B prostate cancers. Under general or spinal anesthesia, an incision is made through a patient's abdomen or

perineal area, and the diseased prostate is removed. The procedure is lengthy, especially if a lymph node dissection is simultaneously performed, and requires a hospital stay of 2-5 days. Possible complications
5 include impotence and urinary incontinence.

Internal radiation therapy or brachytherapy has recently been developed and holds great promise for the treatment of early stage prostate cancer. Radioactive pellets or seeds of, for example, iodine-
10 125, palladium-103, or iridium-192, are deposited directly into the prostate through needle placement. U.S. Patent No. 5,928,130 to Schmidt provides a slightly modified example of such a needle device.

Imaging techniques, such as transrectal
15 ultrasound, CT scans, or MRI, are used to accurately guide placement of the radioactive material. Advantageously, radiation from the brachytherapy seeds is administered directly to the prostate with less damage to surrounding tissues, delivering a
20 substantially higher radiation dosage to the prostate than to the surrounding tissues, as compared to external beam radiation therapy. The procedure need only be performed once, and impotence and urinary incontinence complications are significantly reduced,
25 as compared to prostate removal procedures.

The seeds, which are permanently implanted, give off radiation for weeks or months. Their presence causes little discomfort, and they remain in the prostate after decay of the radioactivity. For several
30 weeks following needle insertion, patients may experience pain in the perineal area, and urine may have a red-brown discoloration.

Although, when performed correctly, brachytherapy may provide several benefits when

compared to prostate removal and other techniques,
current apparatus and methods for delivering the seeds
to target locations within the prostate are sub-optimal
and are subject to practitioner error. Current methods
5 of identifying the depth of needle insertion are
ultrasound imaging or fluoroscopy. The junction of the
base of the prostate and the bladder provides a common
reference plane for needle insertion. Identifying this
critical reference "base" plane is critical to proper
10 needle and seed placement.

A previously known technique for imaging the
base plane is to visualize the plane in either
transverse or sagittal ultrasound imaging. Injection
of contrast agent may facilitate imaging. A catheter,
15 such as a standard Foley catheter, may be inserted into
the patient's urethra proximal of the junction.
Contrast agent comprising aerated K-Y jelly and water,
may then be injected through an end port of the
catheter. The agent moves distally towards the
20 patient's bladder and is visible to an ultrasound
probe, positioned in the patient's rectum, thereby
facilitating imaging. However, bone structure and
muscle may obstruct the image making accurate detection
of tissue boundaries difficult. In the absence of
25 reliable positional data, however, radioactive seeds
may be inadvertently deposited into the patient's
bladder rather than the distal region of the prostate.

Attempts have been made to improve Foley
catheters, as well as to facilitate improved imaging
30 within a body lumen. For example, U.S. Patent No.
5,715,825 to Crowley provides an acoustic imaging
catheter with an inflatable dilation balloon and an
ultrasound transducer. However, while Crowley may
provide improved imaging, the device is mechanically

and electrically complex, and is therefore costly. U.S. Patent No. 5,916,153 to Rhea, Jr. provides a multifunction, modified Foley catheter. The device described in that patent, however, does not solve
5 needle placement limitations present in previously known devices and methods.

In view of the drawbacks associated with previously-known methods and apparatus for radioactive seed placement, it would be desirable to provide
10 methods and apparatus that accurately detect tissue boundaries.

It further would be desirable to provide methods and apparatus that provide reliable detection of the bladder/prostate tissue boundary.

15 It also would be desirable to provide methods and apparatus that may be used in conjunction with a standard brachytherapy apparatus.

Summary of the Invention

In view of the foregoing, it is an object of
20 the present invention to provide methods and apparatus that provide reliable detection of the prostate/bladder tissue boundary.

It is also an object of the present invention to provide methods and apparatus that may be used in
25 conjunction with standard brachytherapy.

In accordance with the principles of the present invention, apparatus and methods are provided comprising an elongated needle and means for detecting the boundary between the prostate and the bladder. The
30 needle includes two conductive traces each having a tip region at the distal end of the needle, and a lumen adapted to receive a column of radioactive seeds for

deposition into the prostate once the distal end of the needle is properly positioned.

Impedance measurement circuitry coupled to the tip region of the conductive traces of the needle
5 detects whether the distal end of the needle extends into the bladder or is disposed fully within the distal portion of the prostate. Once the distal end of the elongated needle penetrates into the mucosal lining of the bladder, the impedance of the tissue or fluid
10 between the conductive traces decreases due to the change in tissue or the presence of fluid in the bladder. In particular, if the needle penetrates the mucosal lining into the bladder, the presence of electrolytes in urine within the bladder results in a
15 rapid decrease in the measured impedance. Thus, the tissue boundary between the prostate and the bladder may be readily detected. The distal end of the needle then may be withdrawn back into the prostate for deposition of the radioactive seeds within the
20 prostate. Thus, the present invention provides an improved method for detecting the tissue boundary between the prostate and the bladder for use in prostate brachytherapy treatment.

Brief Description of the Drawings

25 Additional objects and advantages of the invention will be apparent from the following description, the appended claims, and the accompanying drawings, in which like reference characters refer to like parts throughout, and in which:

30 FIG. 1 is a schematic view of a prior art method of performing prostate brachytherapy;

FIG. 2 is a schematic view detailing the prior art method of imaging the prostate/bladder tissue boundary in greater detail;

FIG. 3 is a side view, partly cut away, of an elongated needle of the present invention;

FIG. 4A is a depiction of a section of the elongated needle of the present invention;

FIG. 4B is a cross section of the elongated needle of the present invention;

FIG. 5A is a depiction of an elongated needle of the present invention with the distal end of the elongated needle projected through the prostate/bladder tissue boundary into the bladder;

FIG. 5B is a depiction of an elongated needle of the present invention after it has been withdrawn back into the prostate from the bladder;

FIG. 6 is a cross section of an embodiment of the elongated needle of the present invention; and

FIGS. 7A, 7B and 7C are schematic depictions of portions of an illustrative tissue boundary detection circuit of the present invention.

Detailed Description of the Preferred Embodiment

Referring now to FIGS. 1 and 2, a prior art method of performing brachytherapy for prostate cancer is described. The method and apparatus are as taught by Peter Grimm, DO, in a pamphlet entitled, "Ultrasound Guided Implantation of the Prostate: A Practical Review Course." As seen in FIG. 1, brachytherapy apparatus 10 comprises transrectal ultrasound probe 12, guide block 14, needle 16, plunger 18, and radioactive seeds 20. Ultrasound probe 12 is advanced through a patient's rectum R to facilitate imaging of the patient's prostate P. Prostate P surrounds urethra U and is just

proximal of bladder **B**. The bladder is surrounded by a mucosal lining **M**. An ultrasonic image of a junction between the prostate and the bladder is acquired, as described below with respect to FIG. 2. Needle 16,
5 loaded with seeds 20 and plunger 18, is then advanced through guide block 14, through the patient's perineum **Pe**, and into prostate **P**, where needle 16 is retracted while plunger 18 is held stationary to sew the seeds in a line within prostate **P**.

10 With reference to FIG. 2, the imaging aspect of the apparatus and method of FIG. 1 is described in greater detail. A catheter, such as a standard Foley catheter, is inserted into the patient's urethra proximal of the patient's prostate/bladder junction. A
15 combination of water and KY jelly is then injected through an end port of the catheter. The combination moves distally towards the patient's bladder and appears to ultrasound probe 12 as contrast agent. Ultrasound probe 12 then provides signals that are
20 converted by a previously known ultrasound system to display ultrasonic image 22 of base plane **BP**, which is located tangent to the distal surface of prostate **P**, i.e. at the prostate/bladder junction. All positions within the prostate are determined relative to base
25 plane **BP** during a prostate brachytherapy procedure.

 Ultrasonic imaging and location determination of base plane **BP** may be unreliable due to irregular ultrasonic images dependent on a density of the water/KY jelly combination at a given location, as well
30 as flow conditions within the bladder and urethra. Thus, there exists a need for reliable apparatus and methods for prostate/bladder boundary detection. While an elongated needle for a prostate cancer brachytherapy

procedure is described, the apparatus and methods described herein for tissue boundary detection may be utilized to detect tissue boundaries in other areas of the body such as subclavian vessel detection.

5 One embodiment of a needle constructed in accordance with the present invention is shown in FIG. 3. Brachytherapy needle device 40 of the present invention includes elongated needle 30, handle 34, wires 36 and 38, and circuitry 43. Circuitry 43
10 contains voltage source 41, and impedance measurement circuitry 42. Needle 30 contains conductive traces 32A and 32B (see FIG. 4B) along its outer circumference and includes a tip region at the distal end of the elongated needle 30.

15 Elongated needle 30 may be removably coupled to handle 34 which is used to position and guide needle 30. In an alternative embodiment, circuitry 43 may be contained within a reusable handle 34. Handle 34 may, for example, be formed from a polymer such as ABS,
20 polystyrene, polyvinyl chloride, polysulfone or other suitable material.

Referring now to FIG. 4A, an expanded view of a portion of needle 30 is described. Needle 30 contains lumen 31 that extends from the proximal end to the
25 distal end of the needle and is adapted to accept a column of radioactive seeds 33 and spacers 34. Preferably, a plunger 18 (see FIG. 1) is inserted through lumen 31 to deposit radioactive seeds 20 (see FIG.1).

30 Referring to FIG. 4B, each of the conductive traces 32A and 32B extend from the proximal end to the distal end of elongated needle 30. Conductive traces 32A and 32B preferably are electrically insulated from each other and body tissue along the entire length of

elongated needle 30. As shown in FIG. 4B, insulation strips 44A and 44B are disposed on the outer surface of needle 30 and insulate conductive traces 32A and 32B from the outer surface of needle 30. Conductive traces 5 32A and 32B are disposed on top of insulation strips 44A and 44B, respectively using techniques that are well-known in the art for forming thin film conductive traces, e.g. by gluing conductive foils, using thin-film deposition techniques, film etching, or laminating 10 conductive foil between heat shrink tubing.

Elongated needle 30 may be made from a conductive material such as a metal or a metallic alloy and may be designed for either single-use or reuse. Insulating strips 44A and 44B may be made from an 15 insulating material such as a nylon or polytetrafluoroethylene (PTFE) material. Conductive traces 32A and 32B may be formed from a metal or a metallic alloy. Suitable materials for conductive traces 32A and 32B include, for example, copper, 20 nickel, or a composite of teflon and silver.

Referring again to FIG. 3, conductive trace 32A is electrically coupled to wire 36, and conductive trace 32B is electrically coupled to wire 38. Wires 36 and 38 are coupled to circuitry 43. Voltage source 41 25 is applied between wires 36 and 38. Impedance measurement circuit 42 continuously measures the impedance between wires 36 and 38. The impedance between wires 36 and 38 indicates how much current is flowing from wire 36 to wire 38. Because wires 36 and 30 38 are electrically insulated from each other and the tissue except in the tip region, current flows between conductive traces 32A and 32B only at the tip region at the distal end of needle 30.

This impedance measuring of the present invention assists a clinician's detection of when the distal end of elongated needle 30 projects into the patient's bladder. When elongated needle 30 is
5 inserted into the prostate, only a small amount of current flows between conductive traces 32A and 32B through tissue in the prostate, which has a relatively high impedance. The impedance measurement circuit 42 continuously measures a high impedance value while the
10 distal end of elongated needle 30 is advanced through the prostate. When the distal end of elongated needle 30 projects into the bladder through the tissue boundary 46 (see FIG. 5A), the current flowing between traces 32A and 32B increases due to the presence of
15 electrolytes in urine within the bladder.

More current flows between wires 36 and 38 when the distal tip of needle 30 extends into the bladder than when the tip is fully disposed in the prostate. Impedance measurement circuitry 42 therefore
20 measures a lower impedance between wires 36 and 38 when the tip regions of conductive traces 32A and 32B of elongated needle 30 project into the bladder. The reduction in impedance between wires 36 and 38 measured by the impedance measurement circuitry 42 indicates to
25 the clinician that the tip region of the elongated needle 30 has penetrated the bladder/prostate boundary 46. The clinician then may withdraw needle 30 proximally as shown in FIG. 5B so that the tip region of elongated needle 30 is again fully within the
30 prostate tissue. Elongated needle 30 then is operated to deposit a column of radioactive seeds and spacers within the prostate using a plunger inserted through lumen 31.

Referring now to FIG. 6, an alternative embodiment of needle 30 of the present invention is described. The outer surface of elongated needle 30 may be coated with non-conductive insulating material 48 that covers the entire outer surface of needle 30 around its circumference. Conductive traces 32A and 32B are disposed on the surface of insulation coating 48 using well known techniques as described for the preceding embodiment.

10 Referring now to FIGS. 7A - 7C an illustrative embodiment of the impedance measurement circuitry is described. The analog portion of the tissue boundary detection circuitry begins with a Wein Oscillator 50 that generates two sinusoidal signals 15 with a frequency between approximately 1 kHz and 30 kHz. The sinusoidal signals are 180° out of phase to acquire a balanced signal to the conductive traces 32A and 32B of needle 30. The frequency is controlled by variable trimmer (R2) 51. The output level is 20 controlled by variable trimmer(R1) 52.

The output level of the Wein Oscillator is adjusted by voltage divider (R9) 53 and (R10) 54. The reduced voltage is applied to Bipolar Drive 55, implemented in (U2A) 56, (U2B) 57 and associated 25 components. (U2A) 56 is a non-inverting amplifier with an approximate gain of 2. (U2B) 57 is an inverting amplifier, also with an approximate gain of 2. Each drive signal is approximately 50 mV peak-to-peak for a total drive of approximately 100 mV peak-to-peak 30 applied to conductive traces 32A and 32B of needle 30.

The bipolar drive signal is applied to conductive traces 32A and 32B through resistor network 58 in the Impedance Stage 59. Resistor network 58 controls the impedance measurement range of conductive

traces 32A and 32B. A high impedance measurement range is determined by resistors (R18) and (R20) and a low impedance measurement range is determined by (R17) and (R19). The resistance values may be adjusted to
5 reflect the characteristics of the targeted tissue and the surrounding mucosa or tissue.

Referring still to FIGS. 7A and 7B, the output of Impedance Stage 59 is applied to Instrumentation Amplifier 61, implemented in (U3A) 63,
10 (U3B) 65, (U4A) 67 and their associated components. The input impedance to Instrumentation Amplifier 61 is normally very high. In this illustration, the input impedance is limited to approximately 1 Mohm by resistor (R60) 62. If the impedance at the tip region
15 of the conductive traces 32A and 32B of the elongated needle 30 is infinite, the full voltage from Bipolar Drive 55, approximately 100 mV is applied to the input of Instrumentation Amplifier 61. As the impedance at the tip region of conductive traces 32A and 32B of
20 needle 30 approaches zero, the voltage applied to the input of Instrumentation Amplifier 61 also approaches zero.

In FIG. 7B, the output from Instrumentation Amplifier 61 is applied to Envelope Detector 71,
25 implemented in (U4B) 73 and its associated components. Envelope Detector 71 removes the high frequency sinusoidal signal and generates a low frequency signal having an amplitude that is a function of the input carrier amplitude. The low frequency output signal
30 from Envelope Detector 71 varies as a function of the impedance of the tissue or mucosa through which the tip region of conductive traces 32A and 32B of the elongated needle 30 passes.

The output of Envelope Detector 71 is negative going and also contains high frequency components of the carrier, which have not been completely filtered. To remove the remaining high
5 frequency components, the signal is passed through 2-pole 500 Hz low pass filter 81, implemented in (U5A) 83 and its associated components.

The final analog stage, Output Amplifier 91, is implemented by (U5B) 93 and associated components.
10 This stage inverts the filtered signal and amplifies it to approximately 4.8 volts when the impedance at the tip region of conductive traces 32A and 32B of needle 30 is infinite. This signal is applied to one of the microprocessor analog to digital inputs.

15 Referring to FIG. 7C, the remaining processing is done digitally in microprocessor (U6) 101. The microprocessor may be for example, a MicroChip Technologies PIC16C73A microprocessor or other suitable microprocessor. The microprocessor
20 processes the input signal and continuously monitors the impedance measured to determine when the distal end of the elongated needle penetrates a tissue boundary. Microprocessor 101 preferably causes an indicator to display a metric corresponding to a sensed value of the
25 tissue impedance.

In an alternative embodiment, the indicator may be a light meter that illuminates in response to the measured impedance as schematically depicted by the array of light emitting diodes in FIG. 7C. The tissue
30 impedance measurement circuit is designed for battery operation and may be powered by two 9-volt cells 103 (see FIG. 7B). Because the power requirement for LEDs is quite high and may adversely affect battery life, a single illuminated LED at the extreme left of the light

meter may indicate a maximum resistance at the distal end of elongated needle 30. As the probe is inserted into the prostate, a portion of the light bar will illuminate. As long as the needle is progressing
5 through relatively homogeneous material, the length of the illuminated section of the bar will remain relatively constant. As the needle passes through a tissue boundary, the illuminated length of the light bar will grow or shrink, depending on the impedance
10 characteristics of the new tissue or mucosa. As the impedance sensed at the distal end of elongated needle 30 approaches zero, all LEDs in the light meter may be illuminated.

Although particular embodiments of the
15 present invention have been described above in detail, it will be understood that this description is merely for purposes of illustration. Specific features of the invention are shown in some drawings and not in others; this is for convenience only, and any feature may be
20 combined with another in accordance with the invention. Further variations will be apparent to one skilled in the art in light of this disclosure and are intended to fall within the scope of the appended claims.